蕈样肉芽肿患者第二原发血液和实体恶性肿瘤风险增加:SEER分析
该回顾性分析基于美国SEER-18登记库2000至2015年6742例蕈样肉芽肿患者,评估第二原发血液或实体恶性肿瘤风险。共511例(7.5%)发生第二癌症,总体SIR为10.15(95%CI 9.29-11.07),其中血液肿瘤SIR 39.71、实体瘤SIR 7.33。女性风险高于男性(P<.05),所有种族和分期均显示SIR升高。
要点
- 蕈样肉芽肿患者第二原发癌症总体风险显著升高,SIR为10.15。
- 血液肿瘤风险升高尤为突出,SIR达39.71。
- 女性、所有种族及所有分期患者均显示第二癌症风险升高。
核心结论
- 蕈样肉芽肿患者被诊断第二原发恶性肿瘤的风险增加,应仔细筛查可辨认的第二恶性肿瘤体征和症状。
研究设计与样本
- 回顾性分析美国SEER-18癌症登记库2000至2015年诊断的蕈样肉芽肿患者,共6742例。
主要发现
- 6742例患者中发生511例(7.5%)第二癌症事件,总体SIR为10.15(95%CI 9.29-11.07)。
- 第二癌症中184例(36.0%)为血液恶性肿瘤,SIR为39.71(95%CI 34.05-46.05)。
- 327例(64.0%)为实体瘤恶性肿瘤,SIR为7.33(95%CI 6.56-8.17)。
- 蕈样肉芽肿患者非霍奇金淋巴瘤、霍奇金淋巴瘤、黑色素瘤、肺癌、女性乳腺癌、前列腺癌、结肠癌和肾癌风险增加。
- 女性风险高于男性(P<.05),所有种族组SIR均显著升高,所有分期均观察到SIR升高。
临床怎么用
- 对蕈样肉芽肿患者应仔细筛查第二恶性肿瘤的可辨认体征和症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized. OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF. DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742). RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF. CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.
引用
- Goyal A, O'Leary D, Goyal K, et al. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol. 2019. PMID: 31374302. doi:10.1016/j.jaad.2019.07.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。